Co-chaired by VHIO’s Director, Josep Tabernero, and Richard L. Schilsky, Chairman of the WIN Consortium, the 12th annual WIN Symposium…
Officially announced at the Spanish Society of Medical Oncology’s (SEOM) General Assembly during its Annual virtual Congress, 18-22 October 2021,…
Marking this October’s Breast Cancer Awareness Month, the new ESMO Clinical Practice Guideline for metastatic breast cancer has just published…
Mutations in the KIT proto-oncogene and dysregulated platelet-derived growth factor receptor (PDGFR) signalling are well-established oncogenic drivers that are found…
Recently published as an open access Mini Review in The FEBS Journal* Sandra Peiró, Principal Investigator of VHIO’s Chromatin Dynamics…
In her latest ESMO perspectives On target column: Multidisciplinary Tumor Boards in harmony: mission impossible?, VHIO’s Elena Garralda, Principal Investigator…
Cholangiocarcinoma (CCA) is a highly aggressive, heterogeneous disease that currently accounts for 15% of all liver cancers and approximately 3%…
Reflective of the relevance of just some of the many VHIO-led studies presented during last week’s virtual 2021 Annual Congress…
Featuring among our pre-selection pick of VHIO (co) led research (1) that has subsequently headlined during this week’s virtual 2021 annual Congress of…
Results from a descriptive case study presented last week at the International Association for the Study of Lung Cancer (IASLC)…
1 September 2021, Utrecht (The Netherlands) – A new international consortium of academic and industrial leaders in the field of cancer…
PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients…
